Luisa Stamm, MD, PhD, is an infectious disease physician and Chief Medical Officer at Assembly Biosciences. She is currently focused on the development of a cure for chronic hepatitis B infection with core inhibitors and other candidates with complementary mechanisms. Prior to her current role, Dr. Stamm worked at Gilead Sciences on the clinical development of sofosbuvir-based therapies for chronic hepatitis C infection and of broadly neutralizing antibodies for HIV cure. Dr. Stamm received her MD and PhD from University of San Francisco, California, and completed her clinical training at Brigham and Women’s Hospital and Massachusetts General Hospital.
